All stock lists
Structure Therapeutics Inc. (NASDAQ:GPCR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
21.10-0.09 (-0.42%)
Market cap
$1.21B
Health Score
Analyst consensus
Listed since
Feb 3, 2023
Website
Insider Score
––Not scored
GPCR Insider Score
Insiders here have filed 9 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
GPCR analyst forecast
GPCR analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
GPCR 12-month price target
No published price targets in the last 12 months.
Best analysts covering GPCR
- HC Wainwright & Co.100%success rate · 5 calls
- Guggenheim100%success rate · 2 calls
- Jefferies50%success rate · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
GPCR analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-09-09 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-08-07 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-16 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-02 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2026-02-27 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-01-22 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-01-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-12-19 |
| — | Citizens | Market Outperform | — | — | Reiterated | 2025-12-12 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-12-12 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-12-11 |
| — | Clear Street | Buy | — | — | Reiterated | 2025-12-09 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-12-09 |
| — | Stifel | Buy | — | — | Reiterated | 2025-12-09 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-07 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-08-07 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-06-23 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-06-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-22 |
| — | Citizens Capital Markets | Market Outperform | — | — | Reiterated | 2025-02-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-20 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-19 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-12-18 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-23 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-16 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-19 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-15 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-08-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-07-01 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-06-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-06-17 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-06-07 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-06-03 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-05-10 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-05-03 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-04-18 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2024-03-08 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2023-11-20 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2023-11-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-10-27 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2023-10-26 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2023-10-03 |
| — | Jefferies | Buy | — | — | Reiterated | 2023-09-29 |
| — | Guggenheim | Buy | — | — | Reiterated | 2023-02-28 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2023-02-28 |
| — | Jefferies | Buy | — | — | Reiterated | 2023-02-28 |
GPCR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-26 | -0.35 | -0.49 | $9.2M | $0 |
| 2026-05-07 | -0.39 | -0.35 | $11.1M | $0 |
| 2026-08-06 | -0.39 | -0.49 | $0 | $0 |
| 2026-11-05 | -0.33 | 0.00 | $50.0M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.